Mouse Anti-Human MSH6
- Known as:
- Mouse Antibody toHuman MSH6
- Catalog number:
- DS-MB-01931
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Ray Biotech
- Gene target:
- Mouse Anti-Human MSH6
Related genes to: Mouse Anti-Human MSH6
- Gene:
- MSH6 NIH gene
- Name:
- mutS homolog 6
- Previous symbol:
- GTBP
- Synonyms:
- -
- Chromosome:
- 2p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-29
- Date modifiied:
- 2019-04-23
Related products to: Mouse Anti-Human MSH6
Related articles to: Mouse Anti-Human MSH6
- Many breast cancer predisposition genes are involved in DNA damage repair, leading to genome instability that can impact immunosurveillance, neoantigen formation, and the composition of the tumor immune microenvironment. - Source: PubMed
Publication date: 2026/05/09
Rojas-Rodríguez FelipeCanisius SanderKeeman RenskeBernstein Aaron JHurson Amber NAhearn Thomas UAndrulis Irene LAntoniou Antonis CBehrens SabineBiałkowska KatarzynaBlows Fiona MBolla Manjeet KCamp Nicola JCessna Melissa HChang-Claude JennyChanock Stephen JDennis JoeDevilee PeterDunning Alison MGronwald JacekHamann UteHollestelle AntoinetteHooning Maartje JHorlings Hugo MJager AgnesJakubowska AnnaJones BrandtKaaks RudolfKok MarleenLissowska JolantaLubiński JanManoochehri MehdiMiller Jodi LMuhammad NoorMulligan Anna MarieObi NadiaRashid Muhammad USinn Hans-Petervan Deurzen Carolien H MWang QinWilliams Justin AYang Xiaohong REaston Douglas FAli H RazaGarcía-Closas MontserratPharoah Paul D PAbubakar MustaphaSchmidt Marjanka K - To explore uptake of risk-reducing gynecologic surgery in a diverse patient population with Lynch syndrome. - Source: PubMed
Publication date: 2026/05/07
Waggoner Rebecca MRicker Charité NNie QiGuo X MonaComeaux Jacob GChang Emmeline YGutierrez NataliaHernandez DaisyNguyen AveriGarcia IvanIto FumitoBrunette Laurie LRoman Lynda DSpicer DarcyCulver Julie O - Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and is generally associated with a favorable prognosis. However, a subset of these tumors exhibits more aggressive behavior, underscoring the need for refined molecular and immunohistochemical characterization to improve diagnostic precision and prognostic stratification. Given the shared embryologic origin of the thyroid gland and gastrointestinal tract from the endoderm, intestinal differentiation markers (CDX2 and SATB2) and alterations in DNA mismatch repair (MMR) pathways, including MLH1 promoter methylation, may represent biologically relevant features in thyroid tumors. This study performed MLH1 promoter methylation analysis by pyrosequencing and protein expression of MLH1, PMS2, MSH2, MSH6, SATB2 and CDX2 by immunohistochemistry in 63 PTCs. Clinicopathological and molecular data were also collected for comparative analyses and correlation with progression-free survival (PFS). All PTCs retained expression of MMR proteins (MLH1, PMS2, MSH2, and MSH6), including the three tumors with MLH1 promoter hypermethylation. CDX2 positivity was detected in only two (3.2%) PTCs (classic and follicular subtypes), and SATB2 expression was absent in all cases. No significant association was identified between MLH1 promoter methylation, MMR protein expression, CDX2 or SATB2 expression, and PFS. In contrast, venous invasion was confirmed as a significant predictor of worse PFS (HR = 3.34; 95% CI 1.27-8.76; p = 0.014) in univariate analysis. MLH1 promoter methylation, MMR deficiency, and CDX2 are rare events in PTC and do not appear to influence PFS. Although infrequent, the expression of CDX2 is not exclusive to any PTC subtype. - Source: PubMed
Publication date: 2026/05/07
Silva Fábio França Vieira EPrada-Ramallal GuillermoDi Domenico MarinaPadín-Iruegas María ElenaRojo-Álvarez Laura IsabelBravo-López Susana BelénDella Monica PaolaColapietra FedericaBallini AndreaCameselle-Teijeiro José Manuel - Malignant teratomas are rare germ cell tumors characterized by undifferentiated embryonic components, exhibiting invasive and metastatic potential. While teratomas commonly arise in the gonads, such as the ovaries and testes, as well as midline locations like the sacrococcygeal region and mediastinum, the occurrence of a malignant teratoma in the femur (right femur) is exceedingly rare, with limited research available. We report the case of a 19-year-old female presented with a subcutaneous mass in the right posterior thigh for 2 months, which was later confirmed as immature teratoma (CK5/6, CK8/18, CK7, CK20, villin , S-100, Syn, GFAP, NF, Neu-N, CgA, CD99, Dasmin, SMA) with higher expression of Ki-67. Two key like pathogenic germline variants were revealed through whole exome sequencing: BLM c.2634C>A (p. Tyr878 *) and MSH6 c.3986C>A (p. Ser1329 *). This report provides information on the clinical course of rare malignant teratoma in the right posterior thigh, including treatment strategy and prognosis. - Source: PubMed
Publication date: 2026/04/21
Shi YanhuiLeng PengfeiTan XiaohuaLiu LinlinZhao Miaoqing - Comprehensive genomic profiling test (CGPT) using next-generation sequencing (NGS) plays a vital role in cancer diagnosis, treatment option, and prognostic evaluation. In Japan, three tissue-based CGPTs, FoundationOne® CDx, GenMineTOP, and NCC OncoGuide™, are reimbursed under public health insurance. However, their comparative performance in central nervous system (CNS) tumors remains unclear. - Source: PubMed
Publication date: 2026/05/06
Kawauchi DaisukeOhno MakotoTakahashi MasamichiKoyama TakafumiSunami KunikoHirata MakotoYanagisawa ShunsukeOmura TakakiAoki TakumaFujii GentaSaito KojiYamamoto TetsuyaSuzuki HiromichiNarita Yoshitaka